SPOTLIGHT -
In November 2021, the FDA approved pafolacianine for use as an imaging drug for identifying lesions in patients with ovarian cancer during surgery.
A Look Behind Development of Pafolacianine for Tumor Detection During Ovarian Cancer Surgery
Philip S. Low, PhD, discusses the obstacles he overcame while creating pafolacianine and what other cancers he hopes will be improved with the use of this agent.
Imaging Drug Pafolacianine Approved by FDA for Detection of Ovarian Cancer During Surgery
Imaging drug pafolacianine was approved by the FDA to detect ovarian cancer lesions in patients during surgery.
Medical World News® Inside the Practice: Phillip Low, PhD, on the Development and Approval of Pafolacianine
CancerNetwork® spoke with Phillip Low, PhD, about the development and FDA approval of pafolacianine.